Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 0.69% is 120% above its 5-year average of -3.47%, near the high end of its 5-year range (-19.97%–2.17%).
58.81% below its 12-month average of 1.67%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 0.36%.
RETURN ON ASSETS (ROA)
0.69%
RETURN ON ASSETS (ROA) AVG TTM
1.67%
RETURN ON ASSETS (ROA) AVG 3Y
0.18%
RETURN ON ASSETS (ROA) AVG 5Y
-3.47%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-58.81%
CURRENT VS 3Y AVG
+272.97%
CURRENT VS 5Y AVG
+119.90%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.37%
median of 787 covered companies
CURRENT VS SECTOR MEDIAN
+102.20%
vs the sector median at left
GoodRx Holdings, Inc.
Market Cap
$1.15B
Return on Assets (ROA)
0.69%
TTM Avg
1.67%
3Y Avg
0.18%
5Y Avg
-3.47%
Market Cap
$1.15B
Return on Assets (ROA)
-14.35%
TTM Avg
-48.83%
3Y Avg
-54.71%
5Y Avg
-49.10%
Market Cap
$1.13B
Return on Assets (ROA)
-57.23%
TTM Avg
-57.23%
3Y Avg
-57.23%
5Y Avg
-57.23%
Market Cap
$1.13B
Return on Assets (ROA)
4.50%
TTM Avg
8.06%
3Y Avg
9.38%
5Y Avg
7.83%
Market Cap
$1.13B
Return on Assets (ROA)
-8.93%
TTM Avg
-2.89%
3Y Avg
-5.64%
5Y Avg
-7.78%
Market Cap
$1.12B
Return on Assets (ROA)
-3.98%
TTM Avg
-7.05%
3Y Avg
-9.66%
5Y Avg
-6.44%
Market Cap
$1.17B
Return on Assets (ROA)
-48.35%
TTM Avg
-102.84%
3Y Avg
-97.55%
5Y Avg
-75.48%
Market Cap
$1.11B
Return on Assets (ROA)
0.81%
TTM Avg
-17.43%
3Y Avg
-5.68%
5Y Avg
0.08%
Market Cap
$1.10B
Return on Assets (ROA)
-117.65%
TTM Avg
-69.65%
3Y Avg
-52.63%
5Y Avg
-41.83%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GoodRx Holdings, Inc. (GDRX) | $1.15B | 0.69% | 1.67% | 0.18% | -3.47% |
| Nektar Therapeutics (NKTR)vs › | $1.15B | -14.35% | -48.83% | -54.71% | -49.10% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | -57.23% | -57.23% | -57.23% | -57.23% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 4.50% | 8.06% | 9.38% | 7.83% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | -8.93% | -2.89% | -5.64% | -7.78% |
| OPKO Health, Inc. (OPK)vs › | $1.12B | -3.98% | -7.05% | -9.66% | -6.44% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | -48.35% | -102.84% | -97.55% | -75.48% |
| STAAR Surgical Company (STAA)vs › | $1.11B | 0.81% | -17.43% | -5.68% | 0.08% |
| Replimune Group, Inc. (REPL)vs › | $1.10B | -117.65% | -69.65% | -52.63% | -41.83% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | -36.19% | -21.98% | -157.70% | -157.70% |
ROA
0.7%
ROE
2.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 2.17% |
| 2024-12-31 | 1.18% |
| 2023-12-31 | -0.56% |
| 2022-12-31 | -2.05% |
| 2021-12-31 | -1.57% |
| 2020-12-31 | -19.97% |
| 2019-12-31 | 17.08% |
| 2018-12-31 | 13.91% |
| 2017-12-31 | 3.08% |
| 2016-12-31 | -2.63% |
